Literature DB >> 18177262

Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate(s).

Israel Schechter1, Etty Ziv.   

Abstract

Many studies suggest that BACE 1 is the genuine beta-secretase; however, this is not undisputed. The wild-type (WT) beta-site of the amyloid precursor protein (APP) present in the worldwide population is cleaved very slowly (kcat/Km: approx. 50 m(-1) s(-1)), while proteases acting on relevant substrates are much more efficient (kcat/Km: 10(4)-10(6) m(-1) s(-1)). Knock-out of BACE 1 in mouse markedly reduces A beta formation. Nevertheless, studies in other systems show that knock-out experiments in rodents and corresponding genetic defects in human may reveal different phenotypes. Considering these issues, we searched for other beta-secretase candidate(s), identified cathepsin D, and evaluated properties of cathepsin D related to BACE 1 that were not examined previously. The kinetic constants (kcat, Km, kcat/Km) for cleaving peptides with beta-sites of the WT or the mutated Swedish families (SW) APP by human BACE 1 and cathepsin D were determined and found to be similar. Western blots reveal that in human brain cathepsin D is approximately 280-fold more abundant than BACE 1. Furthermore, pepstatin A strongly inhibits the cleavage of SW and WT peptides by both brain extracts and cathepsin D, but not by BACE 1. These findings indicate that beta-secretase activity observed in brain extracts is mainly due to cathepsin D. Nevertheless, as both BACE 1 and cathepsin D show poor activity towards the WT beta-site sequence, it is necessary to continue the search for additional beta-secretase candidate(s).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177262     DOI: 10.1515/BC.2008.025

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  15 in total

Review 1.  An overview of APP processing enzymes and products.

Authors:  Vivian W Chow; Mark P Mattson; Philip C Wong; Marc Gleichmann
Journal:  Neuromolecular Med       Date:  2010-03       Impact factor: 3.843

2.  The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species.

Authors:  Jessica Bien; Tamara Jefferson; Mirsada Causević; Thorsten Jumpertz; Lisa Munter; Gerd Multhaup; Sascha Weggen; Christoph Becker-Pauly; Claus U Pietrzik
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

3.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

Review 5.  Alzheimer's disease and the amyloid-beta peptide.

Authors:  M Paul Murphy; Harry LeVine
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors:  Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein.

Authors:  Vivian Y H Hook; Mark Kindy; Thomas Reinheckel; Christoph Peters; Gregory Hook
Journal:  Biochem Biophys Res Commun       Date:  2009-06-06       Impact factor: 3.575

Review 8.  Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.

Authors:  Vivian Hook; Israel Schechter; Hans-Ulrich Demuth; Gregory Hook
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

9.  Lessons from a BACE1 inhibitor trial: off-site but not off base.

Authors:  Debomoy K Lahiri; Bryan Maloney; Justin M Long; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2014-02-12       Impact factor: 21.566

10.  Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology.

Authors:  Yanlin Wang; Gopal Thinakaran; Satyabrata Kar
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.